Safety & Pharmacokinetics Study Of Azacitidine (SC And Oral) In Subjects With MDS, CMML, AML, Lymphoma And Multiple Myeloma
The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.
Acute Myeloid Leukemia|Myelodysplastic Syndromes|Lymphoma|Multiple Myeloma|Leukemia, Myelomonocytic, Chronic
DRUG: azacitidine
To estimate the dose for a given oral formulation that would yield similar exposure [area under the curve (AUC)] to 75 mg/m2 of the subcutaneous formulation., 1 - 18 months
To determine the oral bioavailability of up to 6 different oral formulations in comparison to the subcutaneous formulation, 1 - 18 months|To assess the safety and tolerability of subcutaneous and oral formulations of azacitidine, 1 - 18 months|To assess response rates, 1 - 18 months|To assess RBC transfusion independence, 1 - 18 months|To investigate the pharmacokinetics of oral azacitidine, 1 -18 months|To assess the pharmacodynamic effects of oral azacitidine, 1 -18 months
The purpose of this study is to compare the amount of drug that gets into the bloodstream between different tablets taken by mouth and an injection under the skin.